Chronic Lymphocytic Leukemia | Specialty

Dr. Wierda Discusses Trials of Novel Combinations in CLL

October 7th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia.

Dr. Awan Discusses Venetoclax in CLL

October 3rd 2017

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses venetoclax (Venclexta) in chronic lymphocytic leukemia.

High Response Rate, MRD Negativity Confirmed for Venetoclax in CLL

September 22nd 2017

Treatment with the BCL-2 inhibitor venetoclax (Venclexta) led to negative minimal residual disease (MRD) status in 40% of evaluable patients with relapsed/refractory chronic lymphocytic leukemia.

CAR T-Cell Therapy Active in High-Risk, Refractory CLL

September 20th 2017

Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014.

Venetoclax Combination Improves PFS in Phase III CLL Trial

September 19th 2017

The combination of venetoclax and rituximab significantly improved progression-free survival compared with rituximab plus bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL),

FDA Accepts Application for Rituximab Biosimilar

September 12th 2017

The FDA has accepted a biologics license application for the rituximab biosimilar Rixathon, according to Sandoz, the company developing the treatment.

FDA Places Holds on Several Durvalumab Combination Trials

September 8th 2017

The FDA has placed clinical holds on multiple trials in Celgene’s FUSION program, which is exploring regimens combining the PD-L1 inhibitor durvalumab with immunomodulatory and chemotherapy agents across several hematologic malignancies.

Dr. Chavez on Combination of Ibrutinib Plus Ublituximab in CLL

September 7th 2017

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the potential with the combination of ibrutinib (Imbruvica) and ublituximab (TGR-1101) in patients with chronic lymphocytic leukemia (CLL).

Duvelisib Improves PFS in Phase III CLL Trial

September 7th 2017

Duvelisib reduced the risk of disease progression or death by 48% versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Byrd on Impact of Ibrutinib on Patients With CLL

September 6th 2017

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the long-term impact that ibrutinib (Imbruvica) has on patients with chronic lymphocytic leukemia (CLL).

Dr. Furman on Exciting Available Agents for Patients With CLL

September 1st 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the available agents that have shown promise for patients with chronic lymphocytic leukemia (CLL).

The Value of MRD Testing in Lymphoid Malignancies

August 29th 2017

MRD Negativity in Multiple Myeloma

August 29th 2017

Reliability of MRD Testing: Sensitivity/Specificity

August 29th 2017

Varying Pertinence: MRD Testing Across Lymphomas

August 29th 2017

How to Properly Utilize MRD Testing

August 29th 2017

An Overview of Minimal Residual Disease Testing

August 29th 2017

Understanding MRD Testing in CLL

August 29th 2017

CLL: MRD Testing Platforms

August 29th 2017

MRD Timepoints in CLL

August 29th 2017